Sign up for our daily briefing

Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Stay on top of the latest market trends

Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sports news worthy of your time

Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tech news worthy of your time

Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Get the inside stories

Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Denver news?

Get a daily digest of the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Des Moines news?

Get a daily digest of the most important stories affecting your hometown with Axios Des Moines

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Twin Cities news?

Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Tampa Bay news?

Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Charlotte news?

Get a daily digest of the most important stories affecting your hometown with Axios Charlotte

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Illustration: Sarah Grillo/Axios

All of a sudden, it feels like we're hurtling toward a coronavirus vaccine — with the first doses potentially being administered before the 2020 election.

Why it matters: The question of whether politics influence the Trump administration's actions looms larger than ever. Just as important is the question of whether we'll be ready for this complicated effort in less than two months.

Driving the news: The Centers for Disease Control and Prevention urged governors last week to do everything possible to get vaccine distribution sites operational by Nov. 1, McClatchy reported Wednesday.

  • A few hours later, the New York Times published CDC guidance on how to distribute early doses of two vaccines, including who should receive priority.
  • The vaccines, described as "Vaccine A" and "Vaccine B," match the descriptions of vaccines being developed by Pfizer and Moderna, which are furthest along in clinical trials. Both require two doses and must be stored at sub-zero temperatures.

What they're saying: "This timeline of the initial deployment at the end of October is deeply worrisome for the politicization of public health and the potential safety ramifications," epidemiologist Saskia Popescu told NYT. "It's hard not to see this as a push for a pre-election vaccine."

The bottom line: None of the logistical hurdles in vaccine distribution are insurmountable, in theory. But the U.S. has a dismal track record so far with even moderately difficult problems during this pandemic.

Go deeper

Dec 12, 2020 - Health

FDA authorizes Pfizer's coronavirus vaccine for emergency use

Photo: Robin Utrecht/SOPA Images/LightRocket via Getty Images

The Food and Drug Administration has issued an emergency use authorization for Pfizer-BioNTech's coronavirus vaccine, the agency announced on Friday night.

Why it matters: It's a major milestone in the U.S. fight against COVID-19, clearing the way for the initial rollout of a vaccine that has been found to be 95% effective with no serious side effects.

Meadows hints FDA chief's job is in jeopardy over coronavirus vaccine

Hahn at a Senate hearing Sept. 23. Photo: Alex Edelman-Pool/Getty Images

White House chief of staff Mark Meadows hinted to Food and Drug Administration commissioner Stephen Hahn on a phone call Friday that his job security might be in jeopardy as he pushed the FDA chief to approve Pfizer's coronavirus vaccine by the end of the day, according to two sources familiar with the call.

Why it matters: It's one more example of the White House putting political pressure on the FDA to expedite its green light on a coronavirus vaccine.

Updated 1 hour ago - Politics & Policy

Coronavirus dashboard

Illustration: Aïda Amer/Axios

  1. Tech: "Fludemic" model accurately maps COVID hotspotsVirtual doctor's visits and digital health tools take off.
  2. Politics: Schumer says Senate will stay through weekend to vote on COVID relief — Republican governor of West Virginia says there's no plan to lift mask mandate.
  3. World: Canada vaccine panel recommends 4 months between doses.
  4. Business: Firms develop new ways to inoculate the public.
  5. Local: Ultra-rich Florida community got vaccinations in January.